Skip to main content
    H

    Humacyte Inc (HUMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.54
    -0.02 (-3.24%)

    Market Cap: $155.12M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Humacyte Inc (HUMA) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Humacyte (HUMA) is expected to report earnings on Mar 25, 2027. In the quarter ended Sep 30, 2026, Humacyte reported EPS of -$0.07, above the -$0.09 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    48%(11/23)
    Avg Surprise
    +16.10%
    Streak
    1 Q

    Upcoming Estimates

    Reports Mar 25, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.11 - -$0.05
    8 analysts
    Revenue Consensus
    $2.15M
    Range$1.96M - $2.42M
    7 analysts
    Reports May 11, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.07
    Range-$0.09 - -$0.05
    3 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08+2.3%
    60d ago-$0.07-4.7%
    30d ago-$0.07-4.7%
    7d ago-$0.07-4.7%
    Current-$0.07
    Revenue Consensus
    $2.13M
    Range$1.23M - $3.40M
    4 analysts

    Next Report

    HUMA has an expected report date of Mar 25, 2027.

    HUMA Earnings Call

    The latest HUMA earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 23 quarters below that had an estimate, HUMA beat 11, missed 11 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $1.03M, up 36.8% from $753000 a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.07-$0.09-$0.10 - -$0.06+22.22%BeatN/A41 up, 1 downNov 10, 2026$1.03M
    Jun 30, 2026-$0.16-$0.10-$0.12 - -$0.09-60.00%MissN/A32 up, 0 downAug 12, 2026$406000
    Mar 31, 2026-$0.09-$0.11-$0.13 - -$0.10+18.18%Beat-132.1%41 up, 0 downMay 13, 2026$495000
    Dec 31, 2025-$0.19-$0.13-$0.15 - -$0.13-46.42%MissN/A31 up, 1 downMar 27, 2026$467000
    Sep 30, 2025-$0.11-$0.15-$0.18 - -$0.10+26.67%BeatN/A42 up, 0 downNov 12, 2025$753000
    Jun 30, 2025-$0.24-$0.18-$0.20 - -$0.16-33.33%MissN/A31 up, 1 downAug 11, 2025$301000
    Mar 31, 2025$0.28-$0.21-$0.26 - -$0.15+233.33%BeatN/A41 up, 0 downMay 13, 2025$517000
    Dec 31, 2024-$0.21-$0.26-$0.30 - -$0.22+18.00%BeatN/A40 up, 1 downMar 28, 2025$7.23M
    Sep 30, 2024-$0.26-$0.24-$0.26 - -$0.23-8.33%MissN/A70 up, 0 downNov 8, 2024N/A
    Jun 30, 2024-$0.48-$0.24-$0.25 - -$0.23-100.00%MissN/A50 up, 0 downAug 13, 2024N/A
    Mar 31, 2024-$0.25-$0.23-$0.24 - -$0.21-8.70%MissN/A40 up, 0 downMay 10, 2024N/A
    Dec 31, 2023-$0.24-$0.24-$0.27 - -$0.200.00%In lineN/A70 up, 0 downMar 22, 2024$10.79M
    Sep 30, 2023-$0.24-$0.25-$0.27 - -$0.22+4.00%BeatN/A60 up, 0 downNov 9, 2023N/A
    Jun 30, 2023-$0.18-$0.22-$0.23 - -$0.21+18.18%BeatN/A60 up, 0 downAug 14, 2023N/A
    Mar 31, 2023-$0.22-$0.21-$0.22 - -$0.20-4.76%MissN/A50 up, 0 downMay 12, 2023N/A
    Dec 31, 2022-$0.04-$0.23-$0.25 - -$0.22+82.61%Beat-109.8%60 up, 0 downMar 24, 2023N/A
    Sep 30, 2022-$0.24-$0.22-$0.23 - -$0.19-9.09%MissN/A60 up, 0 downNov 10, 2022$31000
    Jun 30, 2022-$0.19-$0.22-$0.23 - -$0.21+13.64%BeatN/A50 up, 0 downAug 12, 2022$1.30M
    Mar 31, 2022-$0.22-$0.21-$0.22 - -$0.20-4.76%MissN/A60 up, 0 downMay 13, 2022$233000
    Dec 31, 2021$0.41-$0.20-$0.22 - -$0.18+305.00%BeatN/A6N/AMar 29, 2022$177000
    Sep 30, 2021-$0.50-$0.21-$0.23 - -$0.18-138.10%MissN/A6N/ANov 12, 2021$241000
    Jun 30, 2021-$0.76-$0.56-$0.95 - -$0.18-35.71%MissN/A2N/AAug 16, 2021$690000
    Mar 31, 2021-$0.20-$0.90N/A+77.78%BeatN/AN/AN/AMay 17, 2021$155000
    Dec 31, 2020-$0.01N/AN/AN/AN/AN/AN/AN/AFeb 16, 2021$124000
    Sep 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/ANov 12, 2020$914000
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.26, after -$1.20 the year before. It was -$0.01 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.26N/A
    Dec 31, 2024-$1.20N/A
    Dec 31, 2023-$0.88N/A
    Dec 31, 2022-$0.69N/A
    Dec 31, 2021-$1.05N/A
    Dec 31, 2020-$0.01N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,700 words across 10 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,74510
    2026Q2Jun 30, 20264,8239
    2026Q1Mar 31, 20264,9759
    2025Q3Sep 30, 20255,62710
    2025Q2Jun 30, 20254,9879
    2025Q1Mar 31, 20255,2299
    2024Q4Dec 31, 20246,2969
    2024Q3Sep 30, 20245,5639

    2026Q3 Earnings Call

    Opening remarks

    Thomas Johnson LifeSci Advisors Representative Thank you, operator. Before we proceed with the call, I would like to remind everyone that certain statements made during this call are forward-looking statements under U.S. federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements, except as required by law. Information presented on this call is contained in the press release we issued this morning and in our Form 10-Q, which, after filing, may be accessed from the Investor page of the Humacyte website. Joining me on today's call from Humacyte are Dr. Laura Niklason, President and Chief Executive Officer; Jim Mercadante, Chief Commercial Officer; and Dale Sander, Chief Financial Officer and Chief Corporate Development Officer. Dr. Niklason will provide a summary of the company's progress for the third quarter and recent weeks. Jim will provide an update on the commercial transformation and progress with the Symvess market launch, and Dale Sander will review the company's financial results for the quarter ended September 30, 2026. I will now turn the call over to Dr. Niklason. Laura?

    Laura Niklason President and Chief Executive Officer Thank you, Tom, and good morning, everyone. I want to thank you for joining us for our third quarter financial results and business update call. I could not be more excited to share the progress that we're making at Humacyte. What we're doing at Humacyte is exceptionally challenging, and we have created a first-in-class biologic solution that addresses some very significant and broad-based health problems. We have built a team of incredibly talented scientists and other professionals and an outstanding manufacturing facility. I wish that you all had the opportunity to come down and take a tour of our facility. Even representatives from much larger medical device and pharmaceutical organizations walk away in awe of what we have built. I believe that the momentum that we have demonstrated this quarter, along with the upcoming filings and clinical trials, has set the stage for a very significant value creation story in the months and years ahead. It's taken a lot of work to get to this point, and my sincere hope is that we will all look back on today's call as an inflection point for the company. On today's call, after my overview, we'll begin with Jim's review of our commercial progress for Symvess.

    Frequently Asked Questions About HUMA

    When is Humacyte's next earnings date?

    Humacyte's next earnings report is expected for Mar 25, 2027.

    Did HUMA beat earnings estimates last quarter?

    Yes. Humacyte reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.09 estimate, a 22.22% surprise.

    What EPS do analysts expect from HUMA next quarter?

    The consensus EPS estimate for Humacyte for the quarter ending Dec 31, 2026 is -$0.07 from 8 analysts, with estimates from -$0.11 to -$0.05.

    How often does HUMA beat earnings estimates?

    Humacyte beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +22.33%.